The impact of serum 25-hydroxyvitamin D level on migraine headache

Abstract

Objective: To investigate the impact of serum 25-hydroxyvitamin D levels on migraine headache in migraineurs

Patients and Methods: A total of 72 patients were included in the study. Serum vitamin D concentration and its impact on the migraine headache were assessed in migraineurs and migraine subgroups. To assess serum levels of vitamin D, 25(OH) D3 was measured by enzyme-linked immunosorbent assay (ELISA). Patients were categorized as follows based on the results of serum vitamin D measurements. Severity of migraine, average duration and frequency of attacks per month were recorded. The headache diary result (HDR) was determined as: Duration of headache × frequency of headache.

Results: Average vitamin D level was 7.4 ng/ml among patients with migraine with aura group and 8.5 ng/ml in patients with migraine without aura. Severe vitamin D deficiency was detected in 14 (66.7%) patients with migraine with aura and 9 (64.3%) patients with migraine without aura, with no statistically significant difference between the two groups. No significant correlation was found between vitamin D levels and HDR among migraineurs (r=-0.042, p=0.812) as well as in patients with migraine with aura (r=0.044, p=0.842) and in patients with migraine without aura (r=0.059, p=0.842) versus control group with respect to HDR and vitamin D levels. The severity of migraine pain was not associated with vitamin D levels. Serum vitamin D concentration was lower in male patients versus control group.

Conclusion: The impact of vitamin D on the severity and number of migraine attacks is not clear. Further studies are needed to demonstrate the association between vitamin D status and neurological diseases.

Keywords

• Migraine,25-hydroxyvitamin D,headache

References

1. 1. Lateef TM, Cui L, Nelson KB, Nakamura EF, Merikangas KR. Physical Comorbidity of Migraine and Other Headaches in US Adolescents. J Pediatr. 2012;161:308–13.
2. 2. Smitherman TA, Burch R, Sheikh H, Loder E. The prevalence, impact, and treatment of migraine and severe headaches in the United States: a review of statistics from national surveillance studies. Headache 2013;53:427–36.
3. 3. Yoon MS, Katsarava Z, Obermann M, et al. Prevalence of primary headaches in Germany: Results of the German Headache Consortium Study. J Headache Pain. 2012;13:215–23.
4. 4. Battista J, Badcock DR, McKendrick AM. Migraine increases centre-surround suppression for drifting visual stimuli. PLOS One. 2011;6:e18211.
5. 5. Schürks M, Rist PM, Bigal ME, Buring JE, Lipton RB, Kurth T. Migraine and cardiovascular disease: Systematic review and meta-analysis. BMJ. 2009;339:b3914.
6. 6. Ertas M, Baykan B, Orhan EK, et al. One-year prevalence and the impact of migraine and tension-type headache in Turkey: A nationwide home-based study in adults. J Headache Pain. 2012;13:147–57.
7. 7. Buell JS, Dawson-Hughes B. Vitamin D and neurocognitive dysfunction: preventing “D“ecline? Mol. Aspects Med. 2008;29:415–22.
8. 8. Prabhakar P, Majumdar V, Kulkarni GB, Christopher R. Genetic variants of vitamin D receptor and susceptibility to ischemic stroke. Biochem. Biophys. Res. Commun. 2015;456:631–6.

9. 9. Prakash S, Mehta NC, Dabhi AS, Lakhani O, Khilari M, Shah ND. The prevalence of headache may be related with the latitude: A possible role of Vitamin D insufficiency? J Headache Pain. 2010;11:301–7.
10. 10. Andıran N, Çelik N, Akça H, Doğan G. Vitamin D deficiency in children and adolescents. J Clin Res Pediatr Endocrinol. 2012;4:25–9. 11. Motaghi M, et al. Relationship between vitamin D receptor gene polymorphisms and migraine without aura in an Iranian population. Biomed Res Int. 2013;351942.
11. 12. Zandifar A. et al. Vitamin D status in migraine patients: a case-control study. Biomed Res Int. 2014;514782.
12. 13. Asadi B, Khorvash F, Najaran A, Khorvash F. Cyproheptadine versus propranolol in the prevention of migraine headaches in children. Pak J Med Sci. 2012;28:309–11.
13. 14. Kjaergaard M, Eggen AE, Mathiesen EB, Jorde R. Association between headache and serum 25-hydroxyvitamin D; the Tromso Study: Tromso 6. Headache 2012; 52: 1499-505.
14. 15. Virtanen JK, Giniatullin R ,et al. Low serum 25-hydroxyvitamin D is associated with higher risk of frequent headache in middle-aged and older men. Sci Rep. 2017;7: 39697.
15. 16. Mottaghi T, Khorvash F, Askari G, Maracy MR, Maghsoudi RGZ. The relationship between serum levels of vitamin D and migraine. J Res Med Sci. 2013; 18): S66–S70.
16. 17. Kjćrgaard M, Eggen AE, Mathiesen EB, Jorde R. Association Between Headache and Serum 25-Hydroxyvitamin D; the Tromsø Study: Tromsø 6. Headache. 2012;52:1499–505.
17. 18. Thys-Jacobs S. Vitamin D and calcium in menstrual migraine. Headache. 1994;34:544–6.
18. 19. Thys-Jacobs S. Alleviation of migraines with therapeutic vitamin D and calcium. Headache. 1994;34:590–2.
19. 20. Prakash S, Shah ND. Chronic tension-type headache with vitamin D deficiency: Casual or causal association? Headache. 2009;49:1214–22.